Invasive aspergillosis (IA) in liver transplant recipients has poor response rates, and a high mortality rate. This is despite treatment with conventional amphotericin B.
Researchers from Pittsburgh, Pennsylvania, conducted a single-center, retrospective study.
They compared the outcome of liver recipients with IA who received amphotericin B lipid complex (ABLC), with those who received conventional amphotericin B.
The team found that IA was present in 12 ABLC-treated patients and 29 amphotericin B recipients in the historical cohort.
The researchers found that the 60-day mortality rate was lower in the ABLC cohort. They found that 33% of the ABLC patients died, compared with 83% of the amphotericin B patients.
They also determined that only 1 of 4 ABLC recipients with definite IA died, compared with all 11 patients with definite IA in the amphotericin B group.
|33% of the patients treated with amphotericin B lipid complex died, compared with 83% of patients treated with amphotericin B.|
|Clinical Infectious Diseases|
In addition, the 60-day survival probability curve was significantly lower in the amphotericin B group.
The team identified ABLC therapy as the only independent mortality-protective variable (odds ratio, 0.31).
Dr Peter Linden's team concluded, "First-line or early salvage therapy for IA with ABLC was associated with significantly improved survival relative to a comparable historical group treated with amphotericin B".